TEV-48125 for the preventive treatment of chronic migraine

Neurology

Volumn 87, Issue 1, 2016, Pages 41-48

  Bigal, Marcelo E ^a   Dodick, David W ^b   Krymchantowski, Abouch V ^c,d   VanderPluym, Juliana H ^b   Tepper, Stewart J ^e   Aycardi, Ernesto ^a   Loupe, Pippa S ^a   Ma, Yuju ^a   Goadsby, Peter J ^f  

^a Teva Pharmaceuticals   (United States)

^b MAYO CLINIC   (United States)

^c Headache Center of Rio   (United States)

^d American Headache Society   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PLACEBO; TEV 48125; UNCLASSIFIED DRUG; CALCITONIN GENE RELATED PEPTIDE; CENTRAL NERVOUS SYSTEM AGENTS; FREMANEZUMAB; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PAIN INTENSITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TRANSFORMED MIGRAINE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DOSE RESPONSE; IMMUNOLOGY; INJECTION; MEDICAL RECORD; MIDDLE AGED; MIGRAINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; CALCITONIN GENE-RELATED PEPTIDE; CENTRAL NERVOUS SYSTEM AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS; MALE; MEDICAL RECORDS; MIDDLE AGED; MIGRAINE DISORDERS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84977587148     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002801     Document Type: Article

References (31)

1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33: 629-808
2. Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012; 52: 1456-1470
3. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010; 30: 599-609
4. Bigal ME, Sheftell FD, Rapoport AM, Lipton RB, Tepper SJ. Chronic daily headache in a tertiary care population: correlation between the International Headache Society diagnostic criteria and proposed revisions of criteria for chronic daily headache. Cephalalgia 2002; 22: 432-438
5. Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache 2001; 41: 573-578
6. Steiner TJ; World Headache Alliance. Lifting the burden: the global campaign against headache. Lancet Neurol 2004; 3: 204-205
7. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386: 743-800
8. Harwood RH, Sayer AA, Hirschfeld M. Current and future worldwide prevalence of dependency, its relationship to total population, and dependency ratios. Bull World Health Organ 2004; 82: 251-258
9. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008; 71: 559-566
10. Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the Second International Burden of Migraine Study (IBMS-II). Headache 2013; 53: 644-655
11. Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 2015; 35: 478-488
12. Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 2014; 20: 22-33
13. Bigal ME, Bronson B, Walter S, Sudworth M, Huggins JP, Garzone P. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalgia 2013; 34: 483-492
14. Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015; 14: 1081-1090
15. D'Amico D, Tepper SJ. Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat 2008; 4: 1155-1167
16. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 754-762
17. Evers S, Afra J, Frese A, et al. EFNS guidelines on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009; 16: 968-981
18. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebocontrolled phases of the PREEMPT clinical program. Headache 2010; 50: 921-936
19. Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebocontrolled, exploratory phase 2 trial. Lancet Neurol 2014; 13: 1100-1107
20. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014; 13: 885-892
21. Cernuda-Morollon E, Larrosa D, Ramon C, Vega J, Martinez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013; 81: 1191-1196
22. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010; 6: 573-582
23. Storer RJ, Akerman S, Goadsby PJ. Calcitonin generelated peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 2004; 142: 1171-1181
24. Benarroch EE. CGRP: sensory neuropeptide with multiple neurologic implications. Neurology 2011; 77: 281-287
25. Summ O, Charbit AR, Andreou AP, Goadsby PJ. Modulation of nocioceptive transmission with calcitonin generelated peptide receptor antagonists in the thalamus. Brain 2010; 133: 2540-2548
26. Felgenhauer K. Protein size and cerebrospinal fluid composition. Klin Wochenschr 1974; 52: 1158-1164
27. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002; 22: 54-61
28. Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache 2013; 53: 1230-1244
29. Silberstein SD, Blumenfeld AM, Cady RK, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 2013; 331: 48-56
30. Diener HC, Dodick DW, Goadsby PJ, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 2009; 29: 1021-1027
31. Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011; 51: 1358-1373